Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. Gastroenterol Clin North Am 2020 Mar;49(1):105-121
Date
02/09/2020Pubmed ID
32033758DOI
10.1016/j.gtc.2019.10.003Scopus ID
2-s2.0-85078856616 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Nonalcoholic fatty liver disease (NAFLD) is a common form of liver disease, associated with features of the metabolic syndrome. Nonalcoholic steatohepatitis (NASH), the aggressive subtype of NAFLD, can cause progressive fibrosis leading to cirrhosis. With the obesity epidemic, there is an increased health care burden from NASH, one of the most common causes of liver transplantation in the United States. There currently are no Food and Drug Administration-approved medical therapies for NASH. There exists a need for therapeutics to correct the drivers of NASH and to reverse or halt fibrosis progression. This article reviews pharmacologic therapeutics being developed to treat NASH.
Author List
Esteban JPG, Asgharpour AAuthor
James Esteban MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
HumansNon-alcoholic Fatty Liver Disease